文献速递免疫规划

过氧化氢灭活西尼罗河病毒疫苗的临床前开发

Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine.
PubMed 文献 · Vaccine · 2016-12-03

本文介绍一种过氧化氢灭活全病毒西尼罗河病毒疫苗HydroVax-001WNV的规模化生产工艺;小鼠接种后产生强病毒特异性中和抗体并抵抗西尼罗河病毒相关死亡,恒河猴接种后抵抗病毒血症;大鼠GLP毒理研究显示安全性良好,仅注射部位轻微短暂刺激;体外相对效力试验与体内应答相关,2-8°C与40±2°C储存6个月疫苗效力或保护性免疫无丧失。

要点

  • HydroVax-001WNV为过氧化氢灭活全病毒西尼罗河病毒疫苗,已建立规模化生产工艺。
  • 小鼠接种后产生强病毒特异性中和抗体并抵抗西尼罗河病毒相关死亡,恒河猴接种后抵抗病毒血症。
  • 大鼠GLP毒理研究显示安全性良好,临床发现仅限于注射部位轻微短暂刺激。

核心结论

  • 临床前免疫原性、安全性和稳定性结果积极,表明HydroVax-001WNV是有前景的疫苗候选。

研究设计与样本

  • 临床前研究:小鼠和恒河猴免疫原性与保护力评价、大鼠GLP毒理研究、体外相对效力试验及强制降解研究、2-8°C与40±2°C储存6个月稳定性比较。

主要发现

  • 小鼠接种后产生强病毒特异性中和抗体应答并抵抗西尼罗河病毒相关死亡。
  • 恒河猴接种后抵抗西尼罗河病毒血症。
  • 大鼠GLP毒理研究显示安全性良好,临床发现仅限于注射部位轻微短暂刺激。
  • 体外相对效力试验与强制降解研究后的体内应答相关。
  • 2-8°C与40±2°C储存6个月比较,疫苗效力或保护性免疫无丧失。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

West Nile virus (WNV) is a mosquito-transmitted pathogen with a wide geographical range that can lead to long-term disability and death in some cases. Despite the public health risk posed by WNV, including an estimated 3 million infections in the United States alone, no vaccine is available for use in humans. Here, we present a scaled manufacturing approach for production of a hydrogen peroxide-inactivated whole virion WNV vaccine, termed HydroVax-001WNV. Vaccination resulted in robust virus-specific neutralizing antibody responses and protection against WNV-associated mortality in mice or viremia in rhesus macaques (RM). A GLP-compliant toxicology study performed in rats demonstrated an excellent safety profile with clinical findings limited to minor and transient irritation at the injection site. An in vitro relative potency (IVRP) assay was developed and shown to correlate with in vivo responses following forced degradation studies. Long-term in vivo potency comparisons between the intended storage condition (2-8°C) and a thermally stressed condition (40±2°C) demonstrated no loss in vaccine efficacy or protective immunity over a 6-month span of time. Together, the positive pre-clinical findings regarding immunogenicity, safety, and stability indicate that HydroVax-001WNV is a promising vaccine candidate.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Poore EA, Slifka DK, Raué HP, et al. Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine. Vaccine. 2016. PMID: 27919629. doi:10.1016/j.vaccine.2016.11.080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。